NEW YORK (
) hit a new 52-week high Tuesday as it is currently trading at $7.06, above its previous 52-week high of $6.97 with 445,992 shares traded as of 1:06 p.m. ET. Average volume has been 496,500 shares over the past 30 days.
Akorn has a market cap of $643.9 million and is part of the
industry. Shares are up 12.5% year to date as of the close of trading on Monday.
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States. The company has a P/E ratio of 28.4, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
- Practice your AKRX trading strategies and win cash in our stock game.
TheStreet Ratings rates Akorn as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full
52-week high stocks
or get investment ideas from our